Miso
"What a pity Biota management are content to give inventions away, rather than build a factory (like D.Sankyo did)and sell our own product."
The licence model is a low risk model. Not as rewarding either i agree. However, the cost, BTA's share, of taking a product to world market with all its testing etc would be as an estimate $200 million (BTA's share only), which 1) it currently does not have; 2) would require huge dilution of shareholders via issue of new shares or listing in another market (as suggested by Portable Alpha) and 2) is a huge risk of shareholders wealth. Imagine investing such funds and having the Tamiflu v Relenza scenario, wherein Tamiflu captures market due outside influences (Rumsfeld) and perceived ease of use).
Therefore the pursuit of the low risk, lower reward, research, develop, licence / partner model modus operandi of BTA.
cheers
- Forums
- ASX - By Stock
- BTA
- tamiflu end of shelf life roche gilead
tamiflu end of shelf life roche gilead, page-5
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online